BCL‐XL is overexpressed in 90% of PDAC cases, and its expression level increases with the progression from PanIN‐1 to PDAC.37 On the contrary, overexpression of BAX can improve sensitivity to GEM.38 Therefore, the transcriptional regulator Yin Yang‐1 (YY1) becomes a potential druggable target for the development of pancreatic cancer treatments by directly activating BAX gene transcription.39 The gene discussed is BAX; the disease is familial pancreatic carcinoma.